Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (S)-Albuterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 10/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Albuterol SCHEMBL2489838 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL10025126 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Levosalbutamol SCHEMBL29361075 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL122805 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Levosalbutamol SCHEMBL4003 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL121596 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL4913 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| (S)-Albuterol SCHEMBL29496690 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL28434340 | 0.98 | ADRB2 (0.97) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Levosalbutamol SCHEMBL29620266 | 0.98 | TDP1 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43844-E1 | Process for preparing isomers of salbutamol | CIPLA LIMITED (IN) | 2012-12-04 | — | — | US | claimed |
| EP-1349828-A1 | PROCESS FOR PREPARING ISOMERS OF SALBUTAMOL | Cipla Limited (IN) | 2003-10-08 | — | — | EP | claimed |
| WO-2002048090-A1 | PROCESS FOR PREPARING ISOMERS OF SALBUTAMOL | CIPLA LIMITED (IN) | 2002-06-20 | — | — | WO | claimed |
| US-20240033232-A1 | New use of (R)-B2-agonists in treatment of sepsis and acute respiratory distress syndrome | TAN WEN (CN) | 2024-02-01 | — | — | US | disclosed |
| US-20220362174-A1 | Use of R-enantiomer Beta2-agonists for prevent and treatment of pulmonary inflammation and inflammatory remodeling for reduced adverse effects | TAN WEN (CN) | 2022-11-17 | — | — | US | disclosed |
| WO-2022191828-A1 | NEW USE OF (R)-β2-AGONISTS IN TREATMENT OF SEPSIS AND ACUTE RESPIRATORY DISTRESS SYNDROME | TAN WEN (CN) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022057839-A1 | USE OF DRY POWDER INHALATION FORMULATION PREPARED FROM LEVOSALBUTAMOL SULFATE | 苏州君宁新药开发中心有限公司 | 2022-03-24 | — | — | WO | disclosed |
| US-9527878-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527878-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160009748-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009748-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-01-14 | — | — | US | disclosed |
| EP-1349828-A1 | PROCESS FOR PREPARING ISOMERS OF SALBUTAMOL | Cipla Limited (IN) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002048090-A1 | PROCESS FOR PREPARING ISOMERS OF SALBUTAMOL | CIPLA LIMITED (IN) | 2002-06-20 | — | — | WO | disclosed |
| WO-2002048090-A1 | PROCESS FOR PREPARING ISOMERS OF SALBUTAMOL | CIPLA LIMITED (IN) | 2002-06-20 | — | — | WO | disclosed |
| EP-0763010-B1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR INC (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-0763010-A4 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR INC (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0763010-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| US-5545745-A | DISSOLVING MIXTURE OF METHYL-5(2-(1,1-DIMETHYLETHYL)AMINO)-1-HYROXYETHYL)-2-(PHENYL -METHOXY)BENZOATE AND A CHIRAL ACID, SALT FORMATION, COOLING, NEUTRALIZING SALT WITH BASE, REDUCTION, DEBENZYLATION | SEPRACOR, INC. (US) | 1996-08-13 | — | — | US | disclosed |
| WO-1995032178-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1995-11-30 | — | — | WO | disclosed |
| US-5399765-A | Salt formation | SEPRACOR, INC. (US) | 1995-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009748-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM | SERPINE1, PLAT, SERPINB1 | ADRB2 3812/4885ADRB1 2410/4885CYP1A2 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.